Early childhood epileptic encephalopathy (ECEE) is a group of severe forms of epilepsy that manifest early in development, most often in the first or second childhood. This disease is characterized by a high frequency of various seizures, which can vary from generalized to focal. Unlike common epilepsy, ECEE is often accompanied by significant impairment of cognitive and emotional development, which causes a low quality of life in children and their families. Epileptic discharges can lead to damage to the nervous system, which in turn depends on the severity of manifestations and the time of initiation of treatment. Treatment approaches should take into account not only the elimination of seizures, but also the support of overall brain function and the development of the child.
History of the disease and interesting historical facts
Early childhood epileptic encephalopathy was first described in the medical literature in the mid-20th century, although some of the disease's symptoms may have been present in earlier eras. In the 1950s, German neurologist Walter Klaus identified a specific subgroup of epilepsies associated with early onset and a high chance of developing severe neurological impairment. One of the most famous cases is that of George O'Hara, who came to the medical community in the 1960s when his unique form of ECEE, influenced by a genetic mutation, attracted the attention of a group of researchers studying the disease. Interestingly, over the decades, ECEE research has gone through different approaches: from classical neurology to molecular genetics, which has led to new discoveries in the field of pathogenesis and treatment.
Epidemiology
According to various statistical studies, RDEE occurs with a frequency of approximately 1 in 2,000 to 4,000 newborns. The epidemiology of this disease varies significantly depending on geographic and ethnic factors. For example, in some populations, certain mutations in genes associated with epilepsy are observed more frequently, leading to a higher incidence of the disease. In most cases, the disease manifests itself in the first three years of life, making early diagnosis and intervention critical to minimize damage to both the child’s health and future development. About 30% children with RDEE respond to standard anticonvulsant drugs, while the rest require more complex approaches to therapy.
Genetic predisposition to this disease
RDEE has a clear genetic predisposition. Many genes have been identified whose mutations can lead to the development of this disease, including SCN1A, SCN2A, PCDH19 and others. For example, mutations in the SCN1A gene associated with Dravet syndrome can also cause manifestations of RDEE. The most common mutations are usually spontaneous, but a hereditary factor cannot be ruled out, which requires careful genetic counseling for families with a history of diseases. According to large studies, about 30-40% cases of RDEE can be explained by a structural or genetic abnormality, which places genetic diagnostics in a key place in the process of disease detection and an individual approach to treatment.
Risk factors for the development of this disease
There are several risk factors that may predispose to the development of RDEE. These factors may be physiological and chemical. They include:
- Genetic mutations, as mentioned above.
- Maternal infectious diseases during pregnancy, such as rubella or cytomegalovirus.
- Lack of oxygen during childbirth, which can also lead to perinatal damage.
- Exposure to toxic substances such as alcohol or drugs during pregnancy.
- Chronic maternal illnesses, such as diabetes or hypertension, that affect the health of the fetus.
These factors can significantly reduce the chances of healthy development, highlighting the importance of early medical intervention and preventive measures for expectant mothers.
Diagnosis of this disease
Diagnosis of RDEE requires a comprehensive approach and includes several methods to confirm the diagnosis. The main symptoms that should alert doctors include:
- Frequent epileptic seizures with various manifestations.
- Developmental delays, including lack of motor skills.
- Changes in behavior, such as social withdrawal or aggression.
Laboratory tests may include blood tests, tests for genetic mutations, and metabolic disorders. Radiological tests, such as magnetic resonance imaging (MRI), can help identify potential structural changes in the brain that may be responsible for the development of epileptic disorders. Other diagnostics, including video monitoring of electroencephalography (EEG), can provide information about the types of seizures and their frequency. In addition, a differential diagnosis is needed to exclude other forms of epilepsy and neurological disorders, such as disorders based on metabolic or infectious factors.
Treatment
Treatment of RDEE is aimed at controlling symptoms and improving the child’s quality of life. The main approaches include pharmacological and surgical treatments, as well as other modalities. Pharmacological treatment begins with the administration of anticonvulsants such as carbamazepine, valproic acid, and levetiracetam. If standard medications are ineffective, more specific therapies such as the ketogenic diet or targeting other metabolic pathways may be used. Surgery is used in known cases where there are localized foci of excitation in the brain that can be removed. Other forms of support may include physical therapy, occupational therapy, and support from therapists and social workers to help with the child’s integration into society.
List of medications used to treat this disease
Medications used to treat RDEE may include:
- Carbamazepine
- Valproic acid
- Levetiracetam
- Clonazepam
- Pyridoxine (vitamin B6) in case of some specific mutations
The list may be expanded depending on individual factors and the patient's response to therapy.
Disease monitoring
Monitoring of RDEE involves regular consultations with a neurologist and other specialists to assess the child’s condition and the effectiveness of treatment. Diagnostic check-ups are performed at regular intervals to adapt treatment to the patient’s changing needs. The prognosis for children with RDEE depends on the age at which treatment begins, the severity of the disease, and the individual’s response to therapy. Complications may include cognitive decline, social impairment, and even the risk of developing other comorbidities.
Age-related features of the disease
EDEE may present differently across age groups. In newborns, the focus is on seizure and neurodevelopmental management as this is the period when key developmental skills are being formed. In older children, the focus is on supporting cognitive function and interventions that promote integration into education and society. It is also important to recognize that families with children with EDEE may have unique challenges in adapting to and understanding developmental differences.
Questions and Answers
- What are the main symptoms of RDEE?
The main symptoms include frequent epileptic seizures, developmental delays and behavioral disturbances. - How to diagnose RDEE?
The diagnosis is established on the basis of the clinical picture, EEG, MRI and genetic studies. - What treatment is available for children with RDEE?
Treatment includes anticonvulsants, a ketogenic diet, and in some cases surgery. - What is the long-term prognosis for children with RDEE?
The prognosis varies depending on the severity of the disease and the effectiveness of treatment. Some children may achieve normal development, while others may experience permanent cognitive and cognitive impairment. - Is there a genetic test available to detect predisposition to RDEE?
Yes, genetic testing can help identify susceptibility to RDEE and other mutations associated with the disease.
Advice from Dr. Oleg Korzhikov
Dr. Korzhikov recommends that parents who notice suspicious symptoms in their children do not delay a visit to a specialist, as early diagnosis can significantly improve the prognosis. It is also important to actively participate in rehabilitation programs and not avoid social interactions for your child. Parents should remember that the support of family and loved ones plays a major role in the treatment process and the child's adaptation to life.
